CN111109359B - Multifunctional pediococcus acidilactici CCFM1105, fermented food thereof and application - Google Patents
Multifunctional pediococcus acidilactici CCFM1105, fermented food thereof and application Download PDFInfo
- Publication number
- CN111109359B CN111109359B CN201911386342.0A CN201911386342A CN111109359B CN 111109359 B CN111109359 B CN 111109359B CN 201911386342 A CN201911386342 A CN 201911386342A CN 111109359 B CN111109359 B CN 111109359B
- Authority
- CN
- China
- Prior art keywords
- pfos
- ccfm1105
- pediococcus acidilactici
- liver
- capacity
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 241000191998 Pediococcus acidilactici Species 0.000 title claims abstract description 62
- 235000021107 fermented food Nutrition 0.000 title claims description 18
- YFSUTJLHUFNCNZ-UHFFFAOYSA-N perfluorooctane-1-sulfonic acid Chemical compound OS(=O)(=O)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)F YFSUTJLHUFNCNZ-UHFFFAOYSA-N 0.000 claims abstract description 86
- 235000013305 food Nutrition 0.000 claims description 8
- 235000012055 fruits and vegetables Nutrition 0.000 claims description 7
- 235000013365 dairy product Nutrition 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 5
- 239000007787 solid Substances 0.000 claims description 5
- 240000007087 Apium graveolens Species 0.000 claims description 3
- 235000015849 Apium graveolens Dulce Group Nutrition 0.000 claims description 3
- 235000010591 Appio Nutrition 0.000 claims description 3
- 235000016068 Berberis vulgaris Nutrition 0.000 claims description 3
- 241000335053 Beta vulgaris Species 0.000 claims description 3
- 240000007124 Brassica oleracea Species 0.000 claims description 3
- 235000003899 Brassica oleracea var acephala Nutrition 0.000 claims description 3
- 235000011301 Brassica oleracea var capitata Nutrition 0.000 claims description 3
- 235000001169 Brassica oleracea var oleracea Nutrition 0.000 claims description 3
- 240000008067 Cucumis sativus Species 0.000 claims description 3
- 235000010799 Cucumis sativus var sativus Nutrition 0.000 claims description 3
- 244000000626 Daucus carota Species 0.000 claims description 3
- 235000002767 Daucus carota Nutrition 0.000 claims description 3
- 241000192001 Pediococcus Species 0.000 claims description 3
- 235000010627 Phaseolus vulgaris Nutrition 0.000 claims description 3
- 244000046052 Phaseolus vulgaris Species 0.000 claims description 3
- 235000013351 cheese Nutrition 0.000 claims description 3
- 235000015142 cultured sour cream Nutrition 0.000 claims description 3
- 235000021056 liquid food Nutrition 0.000 claims description 3
- 235000013336 milk Nutrition 0.000 claims description 3
- 239000008267 milk Substances 0.000 claims description 3
- 210000004080 milk Anatomy 0.000 claims description 3
- 235000021055 solid food Nutrition 0.000 claims description 3
- 231100000331 toxic Toxicity 0.000 claims description 3
- 230000002588 toxic effect Effects 0.000 claims description 3
- 238000002360 preparation method Methods 0.000 claims description 2
- 241000699670 Mus sp. Species 0.000 abstract description 30
- 230000000968 intestinal effect Effects 0.000 abstract description 23
- 241000186000 Bifidobacterium Species 0.000 abstract description 21
- 241000186660 Lactobacillus Species 0.000 abstract description 21
- -1 diphenyl trinitrophenyl hydrazine free radical Chemical class 0.000 abstract description 21
- 229940039696 lactobacillus Drugs 0.000 abstract description 21
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 13
- 238000001179 sorption measurement Methods 0.000 abstract description 13
- 210000001035 gastrointestinal tract Anatomy 0.000 abstract description 12
- 206010020772 Hypertension Diseases 0.000 abstract description 11
- 208000008589 Obesity Diseases 0.000 abstract description 11
- 206010012601 diabetes mellitus Diseases 0.000 abstract description 11
- 235000020824 obesity Nutrition 0.000 abstract description 11
- 230000003078 antioxidant effect Effects 0.000 abstract description 10
- 208000019423 liver disease Diseases 0.000 abstract description 10
- 206010019842 Hepatomegaly Diseases 0.000 abstract description 9
- 239000003963 antioxidant agent Substances 0.000 abstract description 9
- 208000035475 disorder Diseases 0.000 abstract description 7
- 238000000338 in vitro Methods 0.000 abstract description 7
- 201000010099 disease Diseases 0.000 abstract description 6
- 241000606125 Bacteroides Species 0.000 abstract description 5
- 230000009467 reduction Effects 0.000 abstract description 3
- 210000004185 liver Anatomy 0.000 description 32
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 22
- 241000160321 Parabacteroides Species 0.000 description 20
- 239000000243 solution Substances 0.000 description 18
- 239000000047 product Substances 0.000 description 15
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 14
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 14
- 108010082126 Alanine transaminase Proteins 0.000 description 13
- 241000894006 Bacteria Species 0.000 description 13
- 241000699666 Mus <mouse, genus> Species 0.000 description 13
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 12
- 239000000523 sample Substances 0.000 description 12
- 239000004310 lactic acid Substances 0.000 description 11
- 235000014655 lactic acid Nutrition 0.000 description 11
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 10
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 10
- 210000002966 serum Anatomy 0.000 description 10
- 210000004027 cell Anatomy 0.000 description 9
- 230000001603 reducing effect Effects 0.000 description 9
- 239000006228 supernatant Substances 0.000 description 9
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 8
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 8
- 210000004369 blood Anatomy 0.000 description 8
- 239000008280 blood Substances 0.000 description 8
- 239000000203 mixture Substances 0.000 description 8
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 7
- 235000006708 antioxidants Nutrition 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- 231100000419 toxicity Toxicity 0.000 description 7
- 230000001988 toxicity Effects 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 230000001580 bacterial effect Effects 0.000 description 6
- 238000012258 culturing Methods 0.000 description 6
- 230000006378 damage Effects 0.000 description 6
- 238000011160 research Methods 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 4
- 239000006285 cell suspension Substances 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 230000007547 defect Effects 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 244000005700 microbiome Species 0.000 description 4
- 230000036542 oxidative stress Effects 0.000 description 4
- 239000002244 precipitate Substances 0.000 description 4
- 239000006041 probiotic Substances 0.000 description 4
- 235000018291 probiotics Nutrition 0.000 description 4
- 238000012216 screening Methods 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 206010010774 Constipation Diseases 0.000 description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
- 108020004414 DNA Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 241001052560 Thallis Species 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 230000003064 anti-oxidating effect Effects 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 238000004807 desolvation Methods 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 210000003608 fece Anatomy 0.000 description 3
- 239000007789 gas Substances 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 230000009931 harmful effect Effects 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 230000000813 microbial effect Effects 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 239000002504 physiological saline solution Substances 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 238000012163 sequencing technique Methods 0.000 description 3
- 239000000600 sorbitol Substances 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- 108020004465 16S ribosomal RNA Proteins 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 238000003794 Gram staining Methods 0.000 description 2
- 238000012404 In vitro experiment Methods 0.000 description 2
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 244000174681 Michelia champaca Species 0.000 description 2
- 206010029350 Neurotoxicity Diseases 0.000 description 2
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 2
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 2
- 206010044221 Toxic encephalopathy Diseases 0.000 description 2
- 102000003929 Transaminases Human genes 0.000 description 2
- 108090000340 Transaminases Proteins 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 239000011543 agarose gel Substances 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- YTRQFSDWAXHJCC-UHFFFAOYSA-N chloroform;phenol Chemical compound ClC(Cl)Cl.OC1=CC=CC=C1 YTRQFSDWAXHJCC-UHFFFAOYSA-N 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 238000011109 contamination Methods 0.000 description 2
- 235000018417 cysteine Nutrition 0.000 description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 230000002550 fecal effect Effects 0.000 description 2
- 238000000855 fermentation Methods 0.000 description 2
- 230000004151 fermentation Effects 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 210000003494 hepatocyte Anatomy 0.000 description 2
- TUJKJAMUKRIRHC-UHFFFAOYSA-N hydroxyl Chemical compound [OH] TUJKJAMUKRIRHC-UHFFFAOYSA-N 0.000 description 2
- 239000005457 ice water Substances 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 2
- 239000006166 lysate Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 210000004379 membrane Anatomy 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 230000007135 neurotoxicity Effects 0.000 description 2
- 231100000228 neurotoxicity Toxicity 0.000 description 2
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 description 2
- 238000004321 preservation Methods 0.000 description 2
- 238000003672 processing method Methods 0.000 description 2
- 235000005875 quercetin Nutrition 0.000 description 2
- 229960001285 quercetin Drugs 0.000 description 2
- 150000003254 radicals Chemical class 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- ZFRKQXVRDFCRJG-UHFFFAOYSA-N skatole Chemical compound C1=CC=C2C(C)=CNC2=C1 ZFRKQXVRDFCRJG-UHFFFAOYSA-N 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 239000003643 water by type Substances 0.000 description 2
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 description 1
- BHQCQFFYRZLCQQ-UHFFFAOYSA-N (3alpha,5alpha,7alpha,12alpha)-3,7,12-trihydroxy-cholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 BHQCQFFYRZLCQQ-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 231100000699 Bacterial toxin Toxicity 0.000 description 1
- 239000004380 Cholic acid Substances 0.000 description 1
- 241000193468 Clostridium perfringens Species 0.000 description 1
- 241000252212 Danio rerio Species 0.000 description 1
- RWSOTUBLDIXVET-UHFFFAOYSA-N Dihydrogen sulfide Chemical compound S RWSOTUBLDIXVET-UHFFFAOYSA-N 0.000 description 1
- 208000035240 Disease Resistance Diseases 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 206010015548 Euthanasia Diseases 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- 241000628997 Flos Species 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- 206010019851 Hepatotoxicity Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000997832 Homo sapiens Tyrosine-protein kinase JAK2 Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 229910021578 Iron(III) chloride Inorganic materials 0.000 description 1
- 208000017170 Lipid metabolism disease Diseases 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 description 1
- JEVVKJMRZMXFBT-XWDZUXABSA-N Lycophyll Natural products OC/C(=C/CC/C(=C\C=C\C(=C/C=C/C(=C\C=C\C=C(/C=C/C=C(\C=C\C=C(/CC/C=C(/CO)\C)\C)/C)\C)/C)\C)/C)/C JEVVKJMRZMXFBT-XWDZUXABSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- YXOLAZRVSSWPPT-UHFFFAOYSA-N Morin Chemical compound OC1=CC(O)=CC=C1C1=C(O)C(=O)C2=C(O)C=C(O)C=C2O1 YXOLAZRVSSWPPT-UHFFFAOYSA-N 0.000 description 1
- IOVCWXUNBOPUCH-UHFFFAOYSA-M Nitrite anion Chemical compound [O-]N=O IOVCWXUNBOPUCH-UHFFFAOYSA-M 0.000 description 1
- DZKZCXUIXLRBSY-UHFFFAOYSA-N Oc1ccc2oc(O)c(-c3ccccc3)c(=O)c2c1O Chemical compound Oc1ccc2oc(O)c(-c3ccccc3)c(=O)c2c1O DZKZCXUIXLRBSY-UHFFFAOYSA-N 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 238000012181 QIAquick gel extraction kit Methods 0.000 description 1
- 206010074268 Reproductive toxicity Diseases 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 102000004495 STAT3 Transcription Factor Human genes 0.000 description 1
- 108010017324 STAT3 Transcription Factor Proteins 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 102100033444 Tyrosine-protein kinase JAK2 Human genes 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 239000003098 androgen Substances 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 210000001130 astrocyte Anatomy 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 239000000688 bacterial toxin Substances 0.000 description 1
- 238000003287 bathing Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 239000003613 bile acid Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 230000023852 carbohydrate metabolic process Effects 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 231100000315 carcinogenic Toxicity 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 description 1
- 229960002471 cholic acid Drugs 0.000 description 1
- 235000019416 cholic acid Nutrition 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 239000013068 control sample Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000013872 defecation Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- KXGVEGMKQFWNSR-UHFFFAOYSA-N deoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 KXGVEGMKQFWNSR-UHFFFAOYSA-N 0.000 description 1
- 230000007673 developmental toxicity Effects 0.000 description 1
- 231100000415 developmental toxicity Toxicity 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- MGJZITXUQXWAKY-UHFFFAOYSA-N diphenyl-(2,4,6-trinitrophenyl)iminoazanium Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1N=[N+](C=1C=CC=CC=1)C1=CC=CC=C1 MGJZITXUQXWAKY-UHFFFAOYSA-N 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 239000003344 environmental pollutant Substances 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000009123 feedback regulation Effects 0.000 description 1
- 210000003495 flagella Anatomy 0.000 description 1
- 150000002222 fluorine compounds Chemical class 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 230000004110 gluconeogenesis Effects 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 230000008821 health effect Effects 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 231100000753 hepatic injury Toxicity 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000304 hepatotoxicity Toxicity 0.000 description 1
- 230000007686 hepatotoxicity Effects 0.000 description 1
- 102000054999 human core Human genes 0.000 description 1
- 108700026469 human core Proteins 0.000 description 1
- 229910000037 hydrogen sulfide Inorganic materials 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000007688 immunotoxicity Effects 0.000 description 1
- 231100000386 immunotoxicity Toxicity 0.000 description 1
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 1
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- 210000005027 intestinal barrier Anatomy 0.000 description 1
- 230000007358 intestinal barrier function Effects 0.000 description 1
- 208000028774 intestinal disease Diseases 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- RBTARNINKXHZNM-UHFFFAOYSA-K iron trichloride Chemical compound Cl[Fe](Cl)Cl RBTARNINKXHZNM-UHFFFAOYSA-K 0.000 description 1
- PHTQWCKDNZKARW-UHFFFAOYSA-N isoamylol Chemical compound CC(C)CCO PHTQWCKDNZKARW-UHFFFAOYSA-N 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 238000009630 liquid culture Methods 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 208000018191 liver inflammation Diseases 0.000 description 1
- 210000005228 liver tissue Anatomy 0.000 description 1
- 239000012160 loading buffer Substances 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 239000008518 lycium barbarum polysaccharide Substances 0.000 description 1
- OAIJSZIZWZSQBC-GYZMGTAESA-N lycopene Chemical compound CC(C)=CCC\C(C)=C\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C=C(/C)CCC=C(C)C OAIJSZIZWZSQBC-GYZMGTAESA-N 0.000 description 1
- 229960004999 lycopene Drugs 0.000 description 1
- 235000012661 lycopene Nutrition 0.000 description 1
- 239000001751 lycopene Substances 0.000 description 1
- 230000001926 lymphatic effect Effects 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 238000013227 male C57BL/6J mice Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 239000002068 microbial inoculum Substances 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- UXOUKMQIEVGVLY-UHFFFAOYSA-N morin Natural products OC1=CC(O)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 UXOUKMQIEVGVLY-UHFFFAOYSA-N 0.000 description 1
- 235000007708 morin Nutrition 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 239000005445 natural material Substances 0.000 description 1
- 230000009125 negative feedback regulation Effects 0.000 description 1
- 210000004279 orbit Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000008855 peristalsis Effects 0.000 description 1
- 210000002824 peroxisome Anatomy 0.000 description 1
- 235000021110 pickles Nutrition 0.000 description 1
- 231100000719 pollutant Toxicity 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000002096 quantum dot Substances 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 238000005057 refrigeration Methods 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000007696 reproductive toxicity Effects 0.000 description 1
- 231100000372 reproductive toxicity Toxicity 0.000 description 1
- 210000003705 ribosome Anatomy 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 230000002000 scavenging effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 229940074386 skatole Drugs 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 230000003393 splenic effect Effects 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000004753 textile Substances 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- ZCIHMQAPACOQHT-ZGMPDRQDSA-N trans-isorenieratene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/c1c(C)ccc(C)c1C)C=CC=C(/C)C=Cc2c(C)ccc(C)c2C ZCIHMQAPACOQHT-ZGMPDRQDSA-N 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 1
- 238000004704 ultra performance liquid chromatography Methods 0.000 description 1
- 229910021642 ultra pure water Inorganic materials 0.000 description 1
- 238000001946 ultra-performance liquid chromatography-mass spectrometry Methods 0.000 description 1
- 239000012498 ultrapure water Substances 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 210000003934 vacuole Anatomy 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L19/00—Products from fruits or vegetables; Preparation or treatment thereof
- A23L19/20—Products from fruits or vegetables; Preparation or treatment thereof by pickling, e.g. sauerkraut or pickles
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C13/00—Cream; Cream preparations; Making thereof
- A23C13/12—Cream preparations
- A23C13/16—Cream preparations containing, or treated with, microorganisms, enzymes, or antibiotics; Sour cream
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C19/00—Cheese; Cheese preparations; Making thereof
- A23C19/02—Making cheese curd
- A23C19/032—Making cheese curd characterised by the use of specific microorganisms, or enzymes of microbial origin
- A23C19/0323—Making cheese curd characterised by the use of specific microorganisms, or enzymes of microbial origin using only lactic acid bacteria, e.g. Pediococcus and Leuconostoc species; Bifidobacteria; Microbial starters in general
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/12—Fermented milk preparations; Treatment using microorganisms or enzymes
- A23C9/1203—Addition of, or treatment with, enzymes or microorganisms other than lactobacteriaceae
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L11/00—Pulses, i.e. fruits of leguminous plants, for production of food; Products from legumes; Preparation or treatment thereof
- A23L11/50—Fermented pulses or legumes; Fermentation of pulses or legumes based on the addition of microorganisms
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/065—Microorganisms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
- C12N1/205—Bacterial isolates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/41—Pediococcus
- A23V2400/413—Acidilactici
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Polymers & Plastics (AREA)
- General Health & Medical Sciences (AREA)
- Food Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Biotechnology (AREA)
- Nutrition Science (AREA)
- Obesity (AREA)
- Mycology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Hematology (AREA)
- Zoology (AREA)
- Heart & Thoracic Surgery (AREA)
- Tropical Medicine & Parasitology (AREA)
- Cardiology (AREA)
- Botany (AREA)
- Agronomy & Crop Science (AREA)
- General Engineering & Computer Science (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
Abstract
The pediococcus acidilactici CCFM1105 has good adsorption capacity on PFOS in vitro to reduce PFOS concentration, has good capacity of eliminating diphenyl trinitrophenyl hydrazine free radical, capacity of eliminating hydroxyl free radical and reduction capacity, improves liver enlargement of mice caused by PFOS exposure, improves CAT, SOD and antioxidant capacity levels, improves intestinal flora disorder, reduces abundance of S24-7 family, lactobacillus, bifidobacterium and bacteroides paradoxus in intestinal tracts of the mice, and reduces incidence tendency of diseases such as liver diseases, hypertension, diabetes, obesity and the like.
Description
Technical Field
The invention belongs to the technical field of microorganisms, and particularly relates to multifunctional pediococcus acidilactici CCFM1105, fermented food thereof and application thereof.
Background
The perfluoro compound has good hydrophobic and oleophobic properties, and has good thermal stability, chemical stability and biological stability, so that the perfluoro compound is widely applied to various industries. For garments (e.g., waterproof, stain resistant outdoor apparel) and household textiles (e.g., carpets, upholstery, etc.), take-away food containers, personal care products (e.g., dental floss), and fire fighting foams, among others. In addition, PFOS is one of the final transformation products of many fluorine compounds, and may directly cause harm to human body through environmental exposure, or enter into animal and plant bodies to accumulate in human body through food chain, so it has been receiving more and more attention from researchers. Although PFOS was regarded as a potential contaminant in the early 60's 20 th century, PFOS was detected in human blood and organisms until the 21 st century, and received extensive attention and research on the related aspects. PFOS toxicity and hazards are increasingly recognized, and thus a number of procedures have progressively limited the production and use of PFOS. However, PFOS is still in heavy use in some countries and residual PFOS in the environment may also have a lasting effect on the entire ecosystem for a long time in the future.
Research on the correlation between the PFOS content in blood of the exposed population and possible health effects shows that the PFOS exposure may have a more obvious relationship with the increase of total cholesterol concentration in blood, the increase of blood sugar and blood fat, the increase of the concentration of liver enzymes ALT and ALP and the reduction of body weight. These indications suggest that PFOS may affect liver function, lipid metabolism and immune function in humans. The effects occurring in the human body have been found clearly in mammals, and PFOS has various toxic effects such as hepatotoxicity, immunotoxicity, reproductive toxicity, developmental toxicity, neurotoxicity, and the like. PFOS can cause hepatomegaly, induce mouse liver tissue oxidative stress, increase abnormal free radicals, and possibly be the main cause of liver injury. PFOS exposure causes different degrees of damage to a plurality of immune organs of the immune system of aquatic animals and rodents, causes atrophy and aging of spleen and thymus of the immune organs, and obviously interferes with the expression of splenic interleukins of zebra fish and the apoptosis and the decline of lymphocytes. In an exposure experiment for mice, the high-dose PFOS exposure reduces the proliferation function of T lymphocytes and B lymphocytes of the mice, obviously induces the liver edema degeneration and vacuole formation of the mice, reduces the content of bile acid, and can mediate JAK2/STAT3 channels in astrocytes, cause abnormal TNF-alpha secretion to cause neurotoxicity to interfere with the steady state of estrogen and androgen so as to influence the growth and development.
At present, methods for relieving PFOS toxicity are mostly based on natural chemical substances with high antioxidant activity, such as quercetin, lycium barbarum polysaccharide, morin, trihydroxyisoflavone, lycopene and the like which have relieving effects in research. However, these natural substances are expensive and difficult to obtain, and in addition, the potential hazard to the human body from the large intake is unknown due to the human body's tolerance. Therefore, there is a clear need to find an effective method for effectively relieving PFOS toxicity without other possible harmful effects on the human body.
Disclosure of Invention
This section is for the purpose of summarizing some aspects of embodiments of the invention and to briefly introduce some preferred embodiments. In this section, as well as in the abstract and the title of the invention of this application, simplifications or omissions may be made to avoid obscuring the purpose of the section, the abstract and the title, and such simplifications or omissions are not intended to limit the scope of the invention.
As one aspect of the invention, the invention overcomes the defects in the prior art, and provides pediococcus acidilactici CCFM1105 with the collection number of GDMCC No: 60899.
as another aspect of the present invention, the present invention overcomes the disadvantages of the prior art and provides a fermented food: the fermented food is prepared by fermenting and producing Pediococcus acidilactici CCFM1105, and the fermented food comprises solid food, liquid food and semi-solid food.
As a preferable embodiment of the fermented food of the present invention: the fermented food comprises dairy products, bean products and fruit and vegetable products, and the dairy products comprise milk, sour cream and cheese; the fruit and vegetable products comprise cucumber, carrot, beet, celery and cabbage products.
As another aspect of the invention, the invention overcomes the defects in the prior art and provides the application of pediococcus acidilactici CCFM1105 in preparing non-colonized probiotics in vivo.
As another aspect of the invention, the invention overcomes the defects in the prior art and provides the application of pediococcus acidilactici CCFM1105 in preparing the medicines and health products for relieving the toxic effect of PFOS, and resisting liver diseases, hypertension, diabetes, obesity and the like.
As a preferred embodiment of the application of the present invention: the pediococcus acidilactici CCFM1105 has good adsorption capacity on PFOS in vitro to reduce PFOS concentration, has good capacity of removing diphenyl trinitrophenyl hydrazine free radical (DPPH), hydroxyl free radical removing capacity and reducing capacity, improves liver enlargement caused by PFOS exposure, reduces TNF-alpha content in liver, reduces contents of glutamic-pyruvic transaminase (ALT), glutamic-oxalacetic transaminase (AST) and alkaline phosphatase (ALP) in serum, improves levels of CAT, SOD and antioxidant capacity, improves intestinal flora disorder, reduces abundance of S24-7 family, Lactobacillus (Lactobacillus), Bifidobacterium (Bifidobacterium) and Bacteroides paracasei (Parabacteroides) in intestinal tract, and reduces incidence tendency of diseases such as liver disease, hypertension, diabetes and obesity.
As another aspect of the invention, the invention overcomes the defects in the prior art and provides the application of the fermented food in functional foods for relieving PFOS toxicity, liver disease resistance, hypertension resistance, diabetes resistance and obesity resistance.
The invention has the beneficial effects that: the pediococcus acidilactici CCFM1105 has good adsorption capacity on PFOS in vitro to reduce PFOS concentration, has good capacity of removing diphenyl trinitrophenyl hydrazine free radical (DPPH), hydroxyl free radical removing capacity and reducing capacity, improves hepatomegaly caused by PFOS exposure, reduces the content of TNF-alpha in liver, reduces the content of glutamic-pyruvic transaminase (ALT), glutamic-oxalacetic transaminase (AST) and alkaline phosphatase (ALP) in serum, improves the levels of CAT, SOD and antioxidant capacity, improves intestinal flora disorder, reduces the abundance of S24-7 family, Lactobacillus (Lactobacillus), Bifidobacterium (Bifidobacterium) and Parabacteroides (Parabacteroides) in intestinal tract, and reduces the incidence tendency of diseases such as liver disease, hypertension, diabetes and obesity. The pediococcus acidilactici CCFM1105 can be used for preparing foods, health products and medicines for relieving PFOS toxicity, and has very wide application prospect.
Drawings
In order to more clearly illustrate the technical solutions of the embodiments of the present invention, the drawings needed to be used in the description of the embodiments will be briefly introduced below, and it is obvious that the drawings in the following description are only some embodiments of the present invention, and it is obvious for those skilled in the art to obtain other drawings based on these drawings without inventive exercise. Wherein:
FIG. 1 is a schematic diagram of the concentration change of PFOS after the bacterial strain is resuspended in PFOS with the concentration of 20mg/L in vitro, passes through a 0.22 mu m water-based filter membrane, enters an ultra-high performance liquid chromatography-mass spectrometer after being shaken at 37 ℃ and 200rpm for 12 hours, and is adsorbed.
FIG. 2 shows that the strain of the present invention has the capacity of eliminating diphenyl trinitrophenyl hydrazine free radical (DPPH) and hydroxyl radical eliminating capacity and reducing capacity.
FIG. 3 is a graph showing the change in specific gravity of the liver of mice exposed to PFOS 15 days after the intervention of the strain of the present invention. With the different letter representations having significant differences.
FIG. 4 is a graph showing the levels of ALP, ALT and AST in the serum of mice exposed to PFOS 15 days after the intervention of the strain of the invention. With the different letter representations having significant differences.
FIG. 5 is a graph showing the changes of CAT, SOD and antioxidant ability in the liver of mice exposed to PFOS 15 days after the intervention of the strain of the present invention. With the different letter representations having significant differences.
FIG. 6 is a diagram showing the tumor necrosis factor alpha in the liver of mice exposed to PFOS 15 days after the intervention of the strain of the present invention. With the different letter representations having significant differences.
FIG. 7 is a schematic diagram of the strain of the invention, which shows that after 15 days of intervention, mice are exposed to PFOS, and the diversity of the intestinal flora alpha of the mice is changed; wherein different letter representations have significant differences.
FIG. 8 is a graph showing the change in the abundance of S24-7 family, Lactobacillus (Lactobacillus), Bifidobacterium (Bifidobacterium) and Bacteroides (Parabacteroides) in the intestine of mice exposed to PFOS 15 days after the intervention with the strain of the present invention; with the different letter representations having significant differences.
Detailed Description
In order to make the aforementioned objects, features and advantages of the present invention more comprehensible, embodiments accompanying specific embodiments of the present invention are described in detail below.
In the following description, numerous specific details are set forth in order to provide a thorough understanding of the present invention, but the present invention may be practiced in other ways than those specifically described and will be readily apparent to those of ordinary skill in the art without departing from the spirit of the present invention, and therefore the present invention is not limited to the specific embodiments disclosed below.
Furthermore, reference herein to "one embodiment" or "an embodiment" means that a particular feature, structure, or characteristic described in connection with the embodiment is included in at least one implementation of the invention. The appearances of the phrase "in one embodiment" in various places in the specification are not necessarily all referring to the same embodiment, nor are separate or alternative embodiments mutually exclusive of other embodiments.
The Pediococcus acidilactici (Pediococcus ethanoidurans) CCFM1105 is preserved in the Guangdong province microbial strain preservation center in 11, 11 and 22 days in 2019, the preservation address is No. 59 floor of Michelia media 100, Michelia Tokyo, 5 th, Guangdong province microbial research institute, and the preservation number is GDMCC No: 60899.
the pediococcus acidilactici has the following biological properties:
(1) the characteristics of the thallus are as follows: gram-positive, spherical cell, diameter of 0.8-1.0 μm, no flagellum, no spore;
(2) colony characteristics: the colony is milky white, the edge is neat, round, convex and non-transparent, and the surface is moist and smooth;
(3) growth characteristics: the lowest growth temperature of the strain is 15 ℃, the highest growth temperature is 45 ℃, the strain grows optimally at the temperature of 35-37 ℃, the optimum growth pH is 6.5, and the strain enters a stabilization phase after being cultured for 18 hours;
(5) the in vitro has good capacity of removing diphenyl trinitrophenyl hydrazine free radical (DPPH), hydroxyl free radical removing capacity and reducing capacity;
(6) pediococcus acidilactici CCFM1105 can obviously improve the hepatomegaly of the mice exposed by PFOS;
(7) pediococcus acidilactici CCFM1105 can significantly reduce the levels of ALP, ALT and AST in the serum of mice exposed by PFOS;
(8) pediococcus acidilactici CCFM1105 can obviously improve the levels of CAT, SOD and antioxidant capacity in the liver of a PFOS-exposed mouse.
(9) The pediococcus acidilactici CCFM1105 can obviously reduce the content of TNF-alpha in the liver of a mouse exposed by PFOS;
(10) the pediococcus acidilactici CCFM1105 obviously reduces the abundance of S24-7 family, Lactobacillus, Bifidobacterium and Parabacteroides in intestinal tracts of mice, improves the intestinal flora disorder caused by PFOS exposure, and reduces the occurrence tendency of diseases such as liver disease, hypertension, diabetes, obesity and the like.
The extraction method of the pediococcus acidilactici CCFM1105 comprises the following steps:
separating and screening lactic acid bacteria:
(l) Collecting pickle samples, and enriching the samples in a culture medium containing sorbitol GM17 at 35 ℃ for 12 h;
(2) performing gradient dilution on the enriched sample, then coating the enriched sample on a GM17 solid plate added with 0.02% of olcresol purple, and culturing for 24-48 h;
(3) selecting single bacterial colony with obvious color changing circle and according with the basic morphology of lactobacillus, carrying out plate streaking purification, and screening and separating out lactobacillus;
(4) and culturing the single colony in a liquid GM17 culture solution for 24h, performing gram staining, and selecting gram-positive bacteria for subsequent tests.
(II) preliminary identification of lactic acid bacteria: caldolytic ring assay
(l) Culturing the lactic acid bacteria obtained by screening in the step (I) in a liquid sorbitol GM17 culture solution for 24h, and then centrifuging l mL of culture at 8000rpm for 2 min;
(2) with 0.05M KH 2 PO 4 Washing the solution twice;
(3) resuspending the resulting pellet and streaking on sorbitol GM 17-0.75% CaCO 3 Culturing for 24 hours on the solid culture medium;
(4) selecting bacterial colonies which are obvious in calcium-dissolving ring, round in convex surface, fine, dense and white in color and sterile filaments, and preliminarily determining to be cocci when the bacteria are spherical after gram staining and observed by a microscope.
(III) molecular biological identification of lactic acid bacteria:
(l) Extracting a single-bacterium genome:
A. culturing the lactic acid bacteria obtained by screening in the step (II) overnight, taking l mL of the overnight-cultured bacterial suspension into a 1.5mL centrifuge tube, centrifuging at 10000rpm for 2min, and removing the supernatant to obtain thalli;
B. purging the thalli with l mL of sterile water, centrifuging at 10000rpm for 2min, and removing the supernatant to obtain the thalli;
C. adding 200 μ LSDS lysate, and water-bathing at 80 deg.C for 30 min;
D. adding 200 μ L of phenol-chloroform solution into the thallus lysate, wherein the phenol-chloroform solution comprises Tris saturated phenol, chloroform and isoamylol at a volume ratio of 25:24:1, mixing, centrifuging at 12000rpm for 5-10min, and collecting 200 μ L of supernatant;
E. adding 400 μ L of glacial ethanol or glacial isopropanol into 200uL of supernatant, standing at-20 deg.C for 1h, centrifuging at 12000rpm for 5-10min, and discarding the supernatant;
F. adding 500 μ L70% (volume percentage) of glacial ethanol, resuspending the precipitate, centrifuging at 12000rpm for 1-3min, and discarding the supernatant;
drying in an oven at G.60 ℃ or naturally airing;
H.50μLddH 2 re-dissolving the precipitate with O for PCR;
(2)16S rDNAPCR
A. bacterial 16S rDNA50 μ LPCR reaction system:
10 × Taq buffer, 5 μ L; dNTP, 5. mu.L; 27F, 0.5 μ L; 1492R, 0.5 μ L; taq enzyme, 0.5. mu.L; template, 0.5 μ L; ddH 2 O,38μL。
PCR conditions:
95℃5min;95℃10s;55℃30s;72℃30s;step2-4 30×;72℃5min;12℃2min;
(3) preparing 1% agarose gel, mixing the PCR product with 10000 × loading buffer, loading the sample by 5 μ L, running at 120V for 30min, and performing gel imaging;
(4) and (3) sequencing the PCR product of the 16S rDNA, searching and comparing similarity of the obtained sequence result in GeneBank by using BLAST, selecting a newly discovered strain identified as the strain belonging to pediococcus acidilactici according to the sequencing result, and preserving at-80 ℃ for later use.
Example 1: pediococcus acidilactici CCFM1105 has good PFOS adsorption capacity
The bacterial adsorption is used for purifying and activating the pediococcus acidilactici CCFM1105, inoculating the pediococcus acidilactici CCFM1105 into an MRS liquid culture medium according to the inoculation amount of 1% (v/v), and culturing for 12h at 37 ℃. Then centrifuging at 8000r/min for 5min to collect thallus, collecting precipitate, cleaning with physiological saline, centrifuging at 8000r/min for 5min, and removing precipitate to obtain viable thallus cell, i.e. wet thallus. The wet cells were resuspended in a solution of 20mg/L PFOS to a final cell concentration of 1g dry cells/L (the wet cells were resuspended in ultrapure water containing no PFOS as a blank control). The pH of the PFOS solution containing the inoculum solution was rapidly adjusted to 3.0 using 0.1M NaOH or HCl solution, and the effect of the ionic strength on PFOS adsorption was negligible by adding a small amount of NaOH or HCl (less than 0.5 ml). Subsequently, a 250ml conical flask containing 100ml of the sample solution was subjected to shake culture at 37 ℃ and 200rpm, and after 12 hours, sampling was performed, and 2 parallel experiments were averaged.
Measurement of PFOS adsorption amount: after the adsorption experiment, the sample was centrifuged at 8000r/min for 5min and filtered with a 0.22 μm water membrane, PFOS concentration was measured by UPLC-MS with Waters SYNAPT MS system using an acquisition UPLC BEH c18 column (2.1X 100mm, 1.7 μm, Waters Co.), column temperature 35 ℃ and sample size 1 μ L. Gradient washing was carried out using 100% (v/v) acetonitrile solution (solution A) and 0.1% (v/v) aqueous formic acid solution (solution B) as eluents at a flow rate of 0.3 mL/min.
TABLE 1 gradient elution conditions
t/min | 0-0.5 | 0.5-5.0 | 5.0-7.0 | 7.0-7.5 |
Ratio of solvent A | 70% | 70-100% | 100% | 100-70% |
Mass spectrum conditions: the ionization source is an ESI source; MRM detection; MS + detection; capillary (Capillary); 3.0 kV; conc (vertebral body): 40.00V; source Temperature: 120 ℃; desolvation (Desolvation) temperature: 400 ℃; conc Gas Flow: 50L/h; desolvation Gas Flow: 700L/h, gas flow rate of 0.1 ml/min; proton ratio scan range: 100-; scan time 1s, interval 0.061 s. The results were analyzed with MassLynxV4.1(Waters Corp.); and calculating the PFOS adsorption amount of the lactic acid bacteria according to the concentration difference of the PFOS before and after adsorption. The results are shown in FIG. 1, and the adsorption rate of CCFM1105 to PFOS of 20mg/L is 74.26% + -3.47%.
Example 2: the pediococcus acidilactici CCFM1105 has good capacity of removing diphenyl trinitrophenyl hydrazine free radical (DPPH), hydroxyl free radical removing capacity and reducing capacity in vitro;
after 1mL of Pediococcus acidilactici CCFM1105 whole cell suspension and 1mL of freshly prepared DPPH absolute ethanol solution (0.2mmol/L) are fully mixed, the mixture is subjected to a light-shielding reaction at 37 ℃ for 30 min. DPPH was mixed with PBS (pH7.2) as a control sample, and cultured under the same conditions. After centrifugation at 7000 Xg for 10min, the absorbance was measured at 517nm and the ability of the lactic acid bacteria to scavenge DPPH radicals was calculated according to the following formula:
DPPH radical clearance (%) [1-a517 (sample)/a 517 (control) ] × 100%.
1mL1, 10-phenanthroline 1mLPBS (pH7.2), 1mL Pediococcus acidilactici CCFM1105 whole cell suspension or and 1mLFeSO4 were mixed well (referred to as "mixture 1"). To "mixture 1" was added 1mLH 2 O 2 The absorbance was measured at 536nm in a water bath at 37 ℃ for 1.5h and expressed as A536 (sample). The whole cell suspension in "mixture 1" was replaced with the same volume of distilled water, cultured under the same conditions and tested, and denoted as A536 (blank). H to "mixture 1" is added 2 O 2 The cells were cultured under the same conditions and examined by changing to the same volume of distilled water, and designated as A536 (control). The ability of lactic acid bacteria to scavenge hydroxyl radicals is calculated according to the following formula:
hydroxyl radical clearance (%) [ a536 (sample) -a536 (blank) ]/[ a536 (control) -a536 (blank) ] × 100%
0.5mL of Pediococcus acidilactici CCFM1105 whole cell suspension was mixed with the same volume of potassium ferricyanide (1%) and PBS buffer (pH6.6), and the mixture was shaken to homogenize the system. Distilled water was mixed with potassium ferricyanide and PBS as a blank control. The mixed system was incubated at 50 ℃ for 20min, rapidly cooled, and 0.5mL of 10% trichloroacetic acid was added. After centrifugation at 2000 Xg for 5min, 1mL of the supernatant was mixed with 1mL of 0.1% ferric chloride and reacted for 10 min. The absorbance was then measured at a wavelength of 700nm and Cysteine (Cysteine) was used as a standard for characterizing the reducing power. The results of the experiment are shown in FIG. 2.
Example 3: the pediococcus acidilactici CCFM1105 can obviously improve the hepatomegaly of PFOS exposed mice of 24 male C57BL/6J mice with the age of 6 weeks, and after adapting to the environment for one week, the mice are randomly divided into four groups according to the body weight: blank control group, model group, quercetin intervention group, pediococcus acidilactici CCFM1105 intervention group, each group contains 6 mice, and animal grouping and processing method are shown in Table 2.
TABLE 2 animal experiment grouping and processing method
The mice in example 2 were weighed on day 31, then euthanized, bled from the eye sockets, and the liver was removed and weighed wet to calculate organ coefficients, which were calculated according to the following formula:
liver organ coefficient ═ liver wet weight (g)/euthanasia mouse weight (100g)
The experimental result is shown in figure 3, and the result shows that the mouse hepatomegaly caused by the PFOS exposure can be obviously relieved by taking pediococcus acidilactici CCFM 1105.
Example 4: pediococcus acidilactici CCFM1105 can obviously reduce the levels of ALT, ALP and AST in serum of mice exposed by PFOS
After the blood in the embodiment 3 is taken and stood for one hour, 3500r/min is centrifuged for 15min, and serum is taken for testing. And detecting the contents of ALT, ALP and AST in the serum by using a full-automatic biochemical analyzer. ALT, AST, as a non-specific functional enzyme in the hepatocyte cytoplasm and mitochondria, is released into the blood when hepatocytes are disrupted. ALP is normally excreted by the liver and enters the blood stream via the lymphatic channels and the hepatic sinuses when there is damage to the liver. The experimental result shows (figure 4) that the content of ALT, ALP and AST in the serum of mice exposed by PFOS can be obviously reduced by taking pediococcus acidilactici CCFM 1105. The result shows that the damage of the structure and the function of the liver cell membrane of the mouse caused by PFOS can be obviously relieved by taking the pediococcus acidilactici CCFM 1105.
Example 5: pediococcus acidilactici CCFM1105 can obviously reduce the level of MDA and GSH in liver of mice exposed by PFOS
The liver of the mouse in example 3 was made into 10% homogenate, and the liver was weighed accurately in the proportion of 1:9 (g) to volume (ml), and 9 times of the homogenate was addedMechanically homogenizing the accumulated physiological saline in ice-water bath, fully breaking cells, centrifuging at 5000r/min for 10 minutes, and taking supernatant for determination. The levels of SOD, CAT and antioxidant capacity T-AOC in the liver are determined according to a kit provided by a Nanjing construction kit. CAT is mainly present in peroxisomes and is responsible for H 2 O 2 Reduction of (a) and oxidative protection of unsaturated fatty acids in cell membranes. SOD is important antioxidant enzyme in vivo, and has important scavenging effect on ROS. Antioxidant capacity may indicate the level of oxidative stress the body treats. Experimental results show that (figure 5) the levels of CAT, SOD and antioxidant capacity in the liver of a mouse exposed by PFOS can be obviously improved by taking pediococcus acidilactici CCFM 1105. The result shows that the pediococcus acidilactici CCFM1105 can effectively improve the liver oxidative stress injury caused by PFOS.
Example 6: pediococcus acidilactici CCFM1105 can obviously reduce the content of TNF-alpha in liver of PFOS-exposed mouse
The mouse liver in example 3 was taken to make 10% homogenate, the liver was weighed accurately according to the weight (g): volume (ml): 1:9 ratio, 9 times volume of physiological saline was added, mechanical homogenate was performed in ice water bath condition, cells were broken sufficiently, 5000r/min, centrifugation was performed for 10 minutes, and supernatant liver homogenate was taken for measurement. Cytokine TNF-. alpha.content in the liver cytokine levels were determined according to the ELISA kit (RD) instructions. The experimental result shows that the liver inflammation injury of mice caused by PFOS exposure can be obviously improved by taking the pediococcus acidilactici CCFM1105 (figure 6).
Example 7: the pediococcus acidilactici CCFM1105 can obviously reduce the abundance of S24-7 family, Lactobacillus, Bifidobacterium and Parabacteroides in the intestinal tract of mice exposed by PFOS, improve the intestinal tract disorder caused by PFOS exposure, and reduce the tendency of diseases such as liver disease, hypertension, diabetes, obesity and the like.
Fresh feces from the mice on day 31 of example 3 were taken and total DNA was extracted from the fecal samples of the mice using the feces kit from MP. The specific operation steps are mainly carried out according to the kit instructions. Mouse fecal genome as template, upstream primer 520F (5 ' -AYTGGGYDTAAAGNG-3 '), downstream primer 802R (5 ' -TACNVGGGTAT)CTAATCC-3') is used as a primer to amplify a 16S rDNA V3-V4 region fragment, and the length of a target fragment is about 247 bp. And after the PCR reaction is finished, performing electrophoresis again on all the PCR samples with the observed target bands, preparing 2.0% agarose gel, performing electrophoresis for 40min under the condition of 120V, and after the gel is run, rapidly cutting the target bands under an ultraviolet lamp. Recovery of the target band Gel was carried out according to the QIAquick Gel Extraction Kit Gel recovery Kit instructions. The DNA concentration of the Sample is detected according to a Qubit DNA3.0 Kit, then a library is constructed according to a TurSeq DNA LT Sample Preparation Kit and the description thereof, and finally the concentration is determined on an Illumina Miseq sequencer according to a MiSeq Regent Kit and the description thereof. After the sequencing is finished, single sequences with the sequence length less than 200bp, primer sequences and non-splicing sequences are removed, and the single sequences are overlapped according to the basic groups>10bp standard splicing sequence without mismatch. Defining the sequence with similarity greater than 97% as a classification Unit (OTU), by Ribosomal Database Project (RDP)Bayessclasifier to determine species. Calculating the alpha-diversity and the beta-diversity of the sample to evaluate the flora diversity of the sample. The alpha-diversity was characterized by chao1 and the observed species index, and the results (figure 7) showed that the intestinal flora of the model mice had increased alpha-diversity, indicating that PFOS exposure was accompanied by some degree of intestinal disturbance. The alpha diversity of intestinal flora can be obviously reduced by taking the pediococcus acidilactici CCFM1105, and the intestinal disorder condition can be improved.
After PFOS infection, the abundances of S24-7 family, Lactobacillus (Lactobacillus), Bifidobacterium (Bifidobacterium) and Parabacteroides (Parabacteroides) in feces are increased, while the abundances of S24-7 family, Lactobacillus (Lactobacillus), Bifidobacterium (Bifidobacterium) and Parabacteroides (Parabacteroides) in PFOS infected mice can be significantly reduced by taking Pediococcus acidilactici CCFM11105 (FIG. 8); s24-7 is highly localized in the gastrointestinal tract of warm-blooded animals, gram-negative non-motile anaerobic microorganisms, capable of fermenting a wide variety of carbohydrates, and is involved in the development of nonalcoholic fatty liver disease and hypertension. Lactobacillus (Lactobacillus) is a part of normal gastrointestinal tract and genitourinary apparatus, is common probiotics, and has the condition that the abundance of PFOS model group and contamination model is increased in the lactic acid bacteria prevention experiment, and the lactic acid bacteria may have negative feedback regulation after PFOS exposure. Bifidobacteria (bifidobacteria) are widely present in the human and animal habitat, such as the digestive tract, vagina and oral cavity, and one of the important components of the human and animal intestinal flora can be used as probiotics in the fields of food, medicine and feed. Under normal conditions, intestinal microorganisms in the human body form a relatively balanced state. After PFOS contamination, intestinal microbial balance is disrupted, resulting in intestinal flora disturbance, and certain intestinal microorganisms such as clostridium perfringens proliferate excessively in the intestinal tract and produce harmful substances such as ammonia, amines, hydrogen sulfide, skatole, indole, nitrite, bacterial toxins, and the like, thereby further affecting health conditions. At this time, Bifidobacterium (Bifidobacterium) can generate feedback regulation, increase abundance to inhibit the growth of harmful bacteria, resist the infection of foreign pollutants, synthesize vitamins required by human body, promote the absorption of mineral substances by human body, generate organic acids such as acetic acid, propionic acid, butyric acid and lactic acid to stimulate intestinal peristalsis, promote defecation, prevent constipation and intestinal putrefaction, purify intestinal environment, decompose carcinogenic substances, stimulate the immune system of human body, and improve disease resistance. Bacteroides paraBacteroides (Parabacteroides) is one of human core flora, and in vivo and in vitro experiments show that the Bacteroides Parabacteroides (Parabacteroides) has cholic acid conversion function, can also produce a large amount of succinic acid, can activate an intestinal FXR signal path, improve lipid metabolism disorder, repair intestinal walls and activate intestinal gluconeogenesis, thereby regulating appetite, promoting liver glycogen synthesis and improving host glycometabolism disorder. In addition, the research shows that the content of the Parabacteroides paradise (Parabacteroides) is reduced, and the tendency of the body to suffer from diseases such as obesity, non-alcoholic fatty liver disease, diabetes mellitus and the like is increased. The results show that the pediococcus acidilactici CCFM1105 has the functions of regulating intestinal flora, regulating immunity and intestinal barrier, and reducing the occurrence of liver diseases, hypertension, diabetes and obesity on the basis of relieving PFOS toxicity.
Example 8: fermented food of the pediococcus acidilactici CCFM1105 is prepared by the pediococcus acidilactici CCFM1105 of the invention
Selecting fresh vegetables, washing, juicing, carrying out high-temperature instant sterilization, carrying out high-temperature heat sterilization at 140 ℃ for 2 seconds, immediately cooling to 37 ℃, and inoculating the fermentation agent of the Pediococcus acidilactici CCFM1105 microbial inoculum prepared by the invention to ensure that the concentration of the fermentation agent reaches 10 6 And (3) storing the mixture at a temperature of more than 4 ℃ by refrigeration at CFU/mL to obtain the fruit and vegetable beverage containing the pediococcus acidilactici CCFM1105 viable bacteria.
The invention can be used for preparing other fermented foods by fermenting the pediococcus acidilactici CCFM1105, wherein the fermented foods comprise solid foods, liquid foods and semi-solid foods. The fermented food comprises dairy products, bean products and fruit and vegetable products, wherein the dairy products comprise milk, sour cream and cheese; the fruit and vegetable products comprise cucumber, carrot, beet, celery and cabbage products.
The pediococcus acidilactici CCFM1105 has good adsorption effect on PFOS in vitro; the pediococcus acidilactici CCFM1105 has high antioxidation in the capabilities of removing diphenyl trinitrophenyl hydrazine free radical (DPPH), removing hydroxyl free radical and reducing; the pediococcus acidilactici CCFM1105 obviously improves the hepatomegaly caused by PFOS exposure; the content of TNF-alpha in the liver after PFOS exposure is obviously reduced; the pediococcus acidilactici CCFM1105 obviously reduces the contents of alanine Aminotransferase (ALT), aspartate Aminotransferase (AST) and alkaline phosphatase (ALP) in serum after PFOS exposure; the pediococcus acidilactici CCFM1105 can increase the CAT and GSH content in the liver and improve the anti-oxidation capacity of the liver; the pediococcus acidilactici CCFM1105 can improve the disturbance of intestinal flora after PFOS exposure, reduce the abundance of S24-7 family, Lactobacillus (Lactobacillus), Bifidobacterium (Bifidobacterium) and Parabacteroides (Parabacteroides) in the intestinal tract, and reduce the occurrence tendency of liver disease, constipation, hypertension, diabetes and obesity.
In PFOS model mouse experiments, the liver enlargement of mice caused by PFOS exposure can be obviously improved by taking pediococcus acidilactici CCFM 1105; the content of TNF-alpha in the liver of a mouse exposed by PFOS can be obviously reduced by taking pediococcus acidilactici CCFM 1105; taking pediococcus acidilactici CCFM1105 to reduce ALT, AST and ALP content in serum of mice exposed by PFOS; the content of CAT and GSH in the liver is increased by taking pediococcus acidilactici CCFM1105, and the antioxidation capability of the liver is improved; the administration of the composition can improve the intestinal flora disorder of PFOS-exposed mice, reduce the abundance of S24-7 family, Lactobacillus (Lactobacillus), Bifidobacterium (Bifidobacterium) and Parabacteroides (Parabacteroides) in intestinal tract, normalize the intestinal flora, and reduce the occurrence of liver disease, constipation, hypertension, diabetes and obesity. In vitro experiments show that pediococcus acidilactici CCFM1105 can well adsorb PFOS, can effectively remove diphenyl trinitrophenyl hydrazine free radical (DPPH), can remove hydroxyl free radical, and has good reducing capability.
The invention screens out the probiotics which have high adsorption capacity to the PFOS, are not colonized in a human body and have high oxidation resistance, can inhibit the oxidative stress caused by the PFOS, and can fundamentally remove the PFOS in the human body. The pediococcus acidilactici CCFM1105 can be used for preparing foods, health products and medicines for relieving PFOS toxicity, and has very wide application prospect.
It should be noted that the above-mentioned embodiments are only for illustrating the technical solutions of the present invention and not for limiting, and although the present invention has been described in detail with reference to the preferred embodiments, it should be understood by those skilled in the art that modifications or equivalent substitutions may be made on the technical solutions of the present invention without departing from the spirit and scope of the technical solutions of the present invention, which should be covered by the claims of the present invention.
Claims (4)
1. Pediococcus acidilactici (Pediococcus acililicici) CCFM1105 with the collection number GDMCC No: 60899.
2. a fermented food product characterized by: the fermented food is produced by fermenting the pediococcus acidilactici (pediococcus cidilactici) CCFM1105 as claimed in claim 1, and the fermented food comprises solid food, liquid food or semi-solid food.
3. The fermented food product according to claim 2, wherein: the fermented food is a dairy product, a bean product or a fruit and vegetable product, and the dairy product is milk, sour cream or cheese; the fruit and vegetable product comprises cucumber, carrot, beet, celery or cabbage product.
4. Use of Pediococcus acidilactici (CCFM 1105) according to claim 1 in the preparation of a medicament for alleviating the toxic effects of PFOS.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201911386342.0A CN111109359B (en) | 2019-12-29 | 2019-12-29 | Multifunctional pediococcus acidilactici CCFM1105, fermented food thereof and application |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201911386342.0A CN111109359B (en) | 2019-12-29 | 2019-12-29 | Multifunctional pediococcus acidilactici CCFM1105, fermented food thereof and application |
Publications (2)
Publication Number | Publication Date |
---|---|
CN111109359A CN111109359A (en) | 2020-05-08 |
CN111109359B true CN111109359B (en) | 2022-09-02 |
Family
ID=70504384
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201911386342.0A Active CN111109359B (en) | 2019-12-29 | 2019-12-29 | Multifunctional pediococcus acidilactici CCFM1105, fermented food thereof and application |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN111109359B (en) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI734331B (en) * | 2019-08-14 | 2021-07-21 | 大江生醫股份有限公司 | Use of pineapple extracts for skincare |
CN111500505A (en) * | 2020-05-20 | 2020-08-07 | 兰州大学 | Intestinal tract repairing method for reducing heavy metal residues in vivo by using probiotics |
CN113647458A (en) * | 2021-08-06 | 2021-11-16 | 皇氏集团华南乳品有限公司 | Mixed lactobacillus fermented milk with antioxidant function and preparation method thereof |
CN114752539B (en) * | 2022-05-30 | 2023-03-10 | 四川大学 | Pediococcus ethanol-resistant strain and activation method thereof, microbial inoculum and preparation method and application thereof |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108949640A (en) * | 2018-08-22 | 2018-12-07 | 江南大学 | Bifidobacterium breve CCFM1025, its fermented food and its application |
CN109055269A (en) * | 2018-08-22 | 2018-12-21 | 江南大学 | Bifidobacterium longum baby's subspecies CCFM687, its fermented food and its application |
CN110079485A (en) * | 2019-05-31 | 2019-08-02 | 江南大学 | Alleviate Pediococcus acidilactici CCFM6432, its fermented food and its application of depression |
CN110093286A (en) * | 2019-03-19 | 2019-08-06 | 江南大学 | False chainlet Bifidobacterium CCFM1046, its composition, fermented food, purposes, microbial inoculum and its bacterial preparation process |
CN110093287A (en) * | 2019-03-19 | 2019-08-06 | 江南大学 | False chainlet Bifidobacterium CCFM1045, its composition, fermented food, purposes, microbial inoculum and its bacterial preparation process |
CN110226630A (en) * | 2019-06-28 | 2019-09-13 | 江南大学 | Alleviate multi-functional lactobacillus buchneri CCFM1053, its fermented food and the application of PFOA toxic action |
CN110229769A (en) * | 2019-06-28 | 2019-09-13 | 江南大学 | Alleviate Multifunctional fermentation lactobacillus CCFM1051, its fermented food and the application of PFOA toxic action |
CN110468070A (en) * | 2019-08-19 | 2019-11-19 | 江南大学 | Lactobacillus rhamnosus CCFM1060, its fermented food and bacterial preparation process |
-
2019
- 2019-12-29 CN CN201911386342.0A patent/CN111109359B/en active Active
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108949640A (en) * | 2018-08-22 | 2018-12-07 | 江南大学 | Bifidobacterium breve CCFM1025, its fermented food and its application |
CN109055269A (en) * | 2018-08-22 | 2018-12-21 | 江南大学 | Bifidobacterium longum baby's subspecies CCFM687, its fermented food and its application |
CN110093286A (en) * | 2019-03-19 | 2019-08-06 | 江南大学 | False chainlet Bifidobacterium CCFM1046, its composition, fermented food, purposes, microbial inoculum and its bacterial preparation process |
CN110093287A (en) * | 2019-03-19 | 2019-08-06 | 江南大学 | False chainlet Bifidobacterium CCFM1045, its composition, fermented food, purposes, microbial inoculum and its bacterial preparation process |
CN110079485A (en) * | 2019-05-31 | 2019-08-02 | 江南大学 | Alleviate Pediococcus acidilactici CCFM6432, its fermented food and its application of depression |
CN110226630A (en) * | 2019-06-28 | 2019-09-13 | 江南大学 | Alleviate multi-functional lactobacillus buchneri CCFM1053, its fermented food and the application of PFOA toxic action |
CN110229769A (en) * | 2019-06-28 | 2019-09-13 | 江南大学 | Alleviate Multifunctional fermentation lactobacillus CCFM1051, its fermented food and the application of PFOA toxic action |
CN110468070A (en) * | 2019-08-19 | 2019-11-19 | 江南大学 | Lactobacillus rhamnosus CCFM1060, its fermented food and bacterial preparation process |
Also Published As
Publication number | Publication date |
---|---|
CN111109359A (en) | 2020-05-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN111109359B (en) | Multifunctional pediococcus acidilactici CCFM1105, fermented food thereof and application | |
Singh et al. | Influence of diet on the gut microbiome and implications for human health | |
Rajilić-Stojanović | Function of the microbiota | |
CN110964672B (en) | Pediococcus pentosaceus CCFM1104, and fermented food and application thereof | |
Huang et al. | The hypocholesterolaemic effects of Lactobacillus acidophilus American Type Culture Collection 4356 in rats are mediated by the down-regulation of Niemann-Pick C1-Like 1 | |
CN110229769B (en) | Multifunctional lactobacillus fermentum CCFM1051 for relieving PFOA toxic action, fermented food and application thereof | |
CN111117918B (en) | Multifunctional pediococcus pentosaceus CCFM1107 for relieving PFOS toxic effect, fermented food and application thereof | |
CN108384735B (en) | Lactobacillus plantarum CCFM1019, fermented food thereof and application of lactobacillus plantarum CCFM1019 in preparation of medicines | |
US20220152130A1 (en) | Multifunctional lactobacillus capable of relieving pfoa toxic effects and application thereof | |
CN109182162B (en) | Lactobacillus plantarum with antioxidant capacity and application thereof | |
Zhang et al. | The immunoenhancement effects of sea buckthorn pulp oil in cyclophosphamide-induced immunosuppressed mice | |
Zhu et al. | Preparation and characterization of selenium enriched-Bifidobacterium longum DD98, and its repairing effects on antibiotic-induced intestinal dysbacteriosis in mice | |
CN110226630B (en) | Multifunctional lactobacillus buchneri CCFM1053 for relieving PFOA toxic action, fermented food and application thereof | |
Zhijing et al. | Screening beneficial bacteriostatic lactic acid bacteria in the intestine and studies of bacteriostatic substances | |
CN111088184B (en) | Multifunctional enterococcus faecium CCFM1106, feed additive thereof and application | |
Huligere et al. | Isolation and characterization of lactic acid bacteria with potential probiotic activity and further investigation of their activity by α-amylase and α-glucosidase inhibitions of fermented batters | |
Mu et al. | Lactobacillus plantarum KFY02 enhances the relieving effect of gardenoside on montmorillonite induced constipation in mice | |
Huang et al. | Polysaccharides from soybean residue fermented by Neurospora crassa alleviate DSS-induced gut barrier damage and microbiota disturbance in mice | |
Rezaei et al. | Isolation of lactic acid probiotic strains from Iranian camel milk: technological and antioxidant properties | |
Yang et al. | The beneficial effects of polysaccharide obtained from persimmon (Diospyros kaki L.) on the proliferation of Lactobacillus and gut microbiota | |
Tilwani et al. | Characterization of potential probiotic bacteria Enterococcus faecium MC-5 isolated from the gut content of Cyprinus carpio specularis | |
Xie et al. | Fecal fermentation and high-fat diet-induced obesity mouse model confirmed exopolysaccharide from Weissella cibaria PFY06 can ameliorate obesity by regulating the gut microbiota | |
CN111117916B (en) | Pediococcus pentosaceus CCFM1103 for relieving PFOS toxic effects, and fermented food and application thereof | |
Amoah et al. | Host gut-derived Bacillus probiotics supplementation improves growth performance, serum and liver immunity, gut health, and resistive capacity against Vibrio harveyi infection in hybrid grouper (♀ Epinephelus fuscoguttatus×♂ Epinephelus lanceolatus) | |
CN110684682B (en) | Multifunctional lactobacillus casei CCFM1052 capable of relieving PFOA toxic effect, fermented food and application thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |